A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Gandotinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia; Polycythaemia vera
- Focus Adverse reactions
- Sponsors Eli Lilly
- 10 Apr 2017 Status changed from active, no longer recruiting to completed.
- 04 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017, according to ClinicalTrials.gov record.
- 02 Jun 2015 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.